Business
Voting Rights & Capital
Voting Rights & Capital.
About this update from Hikma Pharmaceuticals Plc
[{"type":"text","content":"\n RNS Number : 4174L Hikma Pharmaceuticals Plc 05 May 2010 \n \n\n \n \n \nHikma Pharmaceuticals PLC - Voting Rights and Capital\n \nLONDON, 6 May 2010 Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 1 May 2010 its capital consists of 193,469,413 ordinary shares with voting rights. There are no shares held in treasury.\n \nThe above figure (193,469,413) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules. \n \n- ENDS -\n \nEnquiries:\n \n\n\n\n\nHikma Pharmaceuticals PLC\n\n\n \n\n\n\n\nHenry Knowles\nCompany Secretary\n \n\n\n+44 20 7399 2760\n \n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \nAbout Hikma\n \nHikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: \"Branded\", \"Injectables\" and \"Generics\" based principally in the Middle East and North Africa (\"MENA\") region, where it is a market leader, the United States and Europe. In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million. For news and other information, please visit www.hikma.com. \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END TVRSSWFMIFSSELI \n ","length":3621,"tagName":"div"}]